Sahajanand Medical Technologies vs Shellz India vs Zetwerk IPO: A Comparative Analysis

Sahajanand Medical Technologies, Shellz India, and Zetwerk are all set to close their IPOs on October 19, 2026. Each of these companies operates in distinct sectors, and investors may need to evaluate their options carefully given the varying business fundamentals and subscription demand.

Side-by-Side Comparison

Sector and Business Overview

Sahajanand Medical Technologies operates in the hospital sector, focusing on innovative medical devices, particularly in heart interventions. The company has a strong research and development emphasis and a global presence in over 76 countries. Shellz India, in the packaged foods sector, specializes in confectionery products and maintains a diverse portfolio with a robust distribution network. Zetwerk, in the IT-enabled services sector, connects enterprises with manufacturing partners, leveraging a technology-driven platform to serve various industries.

GMP and Subscription Demand

In terms of Grey Market Premium (GMP), Shellz India shows the strongest performance with a GMP of 46.0, reflecting a 25.7% premium. Sahajanand Medical Technologies follows with a GMP of 24.0, indicating a 6.98% premium. Zetwerk has the lowest GMP at 3.5, corresponding to a 2.32% premium. Subscription demand also varies significantly among these IPOs. Shellz India has a total subscription of 58.54 times, with particularly high demand from non-institutional investors, while Sahajanand Medical Technologies has a total subscription of 14.21 times, showing solid interest across all categories. Zetwerk's subscription stands at 3.1 times, indicating lower demand compared to the other two.

Issue Size and Investment Considerations

Sahajanand Medical Technologies has an issue size of ₹475.48 crore, while Shellz India's issue size is considerably smaller at ₹59.97 crore. Zetwerk has the largest issue size at ₹5012.33 crore, which may influence investor interest due to the scale of operations. The minimum investment required for Sahajanand is ₹14,792, Shellz India requires a significantly higher minimum investment of ₹286,400 due to its lot size, and Zetwerk's minimum investment is relatively accessible at ₹14,949.

Strengths and Weaknesses

Each company has distinct strengths. Sahajanand Medical Technologies boasts a strong product portfolio and global reach, although it faces challenges with a high debt-to-equity ratio and recent financial fluctuations. Shellz India benefits from a well-established distribution network and product differentiation but lacks detailed weaknesses in the provided data. Zetwerk's strengths lie in its unique business model and technology platform, though no weaknesses were specified.

Disclaimer: This is an objective comparison of publicly available IPO data, not investment advice or a personal recommendation to apply for any specific IPO. GMP is unofficial and unregulated. TopFund is not a SEBI-registered investment adviser — please do your own research or consult a qualified adviser before applying.